GOSS supply chain intelligence for Gossamer Bio, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: -offs related to Sandoz’s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Trepr… |
| XOMA | XOMA Royalty Corporation | 72% | Reciprocal relationship from XOMA graph: million. Receipts pursuant to the Daré RPAs were negligible in 2025. DSUVIA - Talphera Commercial Payment Purchase Agreement In January 2024, we acquired an e… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHIESI | CHIESI | 92% | During the three months ended March 31, 2026, Chiesi was the Company's principal customer, accounting for 100 % of its revenue. |
| LQDA | Liquidia Corporation | 72% | Reciprocal relationship from LQDA graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA graph: Reciprocal relationship from GOSS graph: Reciprocal relationship from LQDA g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GOSS-DEBT | Debt stack $202.9M | 90% | Market cache reports total debt of $202.9M. |
| GOSS-DEBT-4766 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| GOSS-DEBT-4765 | Warrants outstanding: 32467360 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GOSS-OWNER-PALO-ALTO-INVESTORS-LP | Palo Alto Investors Lp | 95% | 13F/ownership overlay lists Palo Alto Investors Lp; shares held 5,464,349; ownership 2.36%; value $12.7M; as of 2025-09-30. |
| GOSS-OWNER-HHLR-ADVISORS-LTD | HHLR Advisors, LTD | 95% | 13F/ownership overlay lists HHLR Advisors, LTD; shares held 4,974,041; ownership 2.15%; value $11.5M; as of 2025-09-30. |
| GOSS-OWNER-NEA-MANAGEMENT-COMPANY-LLC | NEA Management Company, LLC | 95% | 13F/ownership overlay lists NEA Management Company, LLC; shares held 18,093,034; ownership 7.82%; value $42.0M; as of 2025-09-30. |
| GOSS-OWNER-SIREN-L-L-C | Siren, L.L.C. | 95% | 13F/ownership overlay lists Siren, L.L.C.; shares held 5,208,968; ownership 2.25%; value $12.1M; as of 2025-09-30. |
| GOSS-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 13,846,054; ownership 5.98%; value $32.1M; as of 2025-09-30. |
| GOSS-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 12,873,209; ownership 5.56%; value $29.9M; as of 2025-12-31. |
| GOSS-OWNER-ARCH-VENTURE-MANAGEMENT-LLC | Arch Venture Management, Llc | 95% | 13F/ownership overlay lists Arch Venture Management, Llc; shares held 8,055,916; ownership 3.48%; value $18.7M; as of 2025-09-30. |
| GOSS-OWNER-OCTAGON-CAPITAL-ADVISORS-LP | Octagon Capital Advisors LP | 95% | 13F/ownership overlay lists Octagon Capital Advisors LP; shares held 17,050,000; ownership 7.37%; value $39.6M; as of 2025-09-30. |
| GOSS-OWNER-683-CAPITAL-MANAGEMENT-LLC | 683 Capital Management LLC | 95% | 13F/ownership overlay lists 683 Capital Management LLC; shares held 5,059,200; ownership 2.19%; value $11.7M; as of 2025-09-30. |
| GOSS-OWNER-SAMSARA-BIOCAPITAL-LLC | Samsara BioCapital, LLC | 95% | 13F/ownership overlay lists Samsara BioCapital, LLC; shares held 6,130,268; ownership 2.65%; value $14.2M; as of 2025-09-30. |
| GOSS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 193 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 100.00 | 2 | |
| NVSEF | Novartis AG | 100.00 | 2 | |
| PLX | Protalix BioTherapeutics, Inc. | 100.00 | 2 | |
| KROS | Keros Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| XOMA | XOMA Royalty Corporation | 100.00 | 1 | ['supplier'] |
| CHIESI | CHIESI | 63.48 | 1 | ['receiving'] |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| GILD | Gilead Sciences, Inc. | 50.00 | 2 | |
| GSK | GSK plc | 50.00 | 2 | |
| IBIO | iBio, Inc. | 50.00 | 2 | |
| DNLI | Denali Therapeutics Inc. | 50.00 | 2 | |
| LADX | LadRx Corporation | 50.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 50.00 | 2 | |
| SRPT | Sarepta Therapeutics, Inc. | 50.00 | 2 | |
| SRRK | Scholar Rock Holding Corporation | 50.00 | 2 | |
| MNPR | Monopar Therapeutics Inc. | 50.00 | 2 | |
| SNYNF | Sanofi | 50.00 | 2 | |
| TAK | Takeda Pharmaceutical Company Limited | 50.00 | 2 | |
| RNAM | Avidity Biosciences, Inc. | 50.00 | 2 | |
| MSLE | Satellos Bioscience Inc. | 50.00 | 2 |